Home › Funds › Rhenman & Partners Asset Management AB › IOVA

Rhenman & Partners Asset Management AB position in IOVA

IOVANCE BIOTHERAPEUTICS INC · Health Care

Rhenman & Partners Asset Management AB reported holding 2,502,577 shares of IOVA (IOVANCE BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$37.1M, representing 4.11% of its reported portfolio and ranking #1 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed IOVA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.50M sh
Reported value held$37.09M
Portfolio Weight4.11%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Rhenman & Partners Asset Management AB's IOVA position evolved

Rhenman & Partners Asset Management AB first disclosed a stake in IOVA in Q3 2023 at 950,000 shares (US$4.3M). The position peaked in Q3 2026 at 2,502,577 shares, worth US$37.1M. Across 13 filings, Rhenman & Partners Asset Management AB increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,502,577 shares valued at US$37.1M — an increase of 797,250 shares quarter over quarter.. Notable position changes include a 48% trim in Q1 2025 (shares fell 48% over the following quarter), a 69% increase in Q3 2025 (shares rose 26% over the following quarter), a 47% increase in Q3 2026 (shares fell 48% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 950.00K $4.32M New
Q4 2023 1.12M $9.08M Add
Q1 2024 955.00K $14.15M Reduce
Q2 2024 920.00K $7.38M Reduce
Q3 2024 1.05M $9.88M Add
Q4 2024 1.24M $9.14M Add
Q1 2025 647.83K $2.16M Reduce
Q2 2025 647.83K $1.11M Hold
Q3 2025 1.10M $2.38M Add
Q4 2025 1.60M $4.36M Add
Q1 2026 2.06M $7.21M Add
Q2 2026 1.71M $7.09M Reduce
Q3 2026 2.50M $37.09M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IOVA and 13F data

IOVA (IOVANCE BIOTHERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in IOVA — the largest reported positions include MHR FUND MANAGEMENT LLC (US$120.5M), Orion Investment Co (US$30.9M), XCELSIOR ADVISOR PARTNERS LLC (US$27.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IOVA

All IOVA fund holders →

FAQ

How long has Rhenman & Partners Asset Management AB held IOVA?

Rhenman & Partners Asset Management AB has disclosed IOVA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Rhenman & Partners Asset Management AB's current position in IOVA?

As of Q3 2026, Rhenman & Partners Asset Management AB holds 2.50M shares of IOVA (IOVANCE BIOTHERAPEUTICS INC), valued at $37.09M, representing 4.11% of its reported portfolio and ranking #1.

Has Rhenman & Partners Asset Management AB been buying or selling IOVA?

In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB increased its position in IOVA. The position peaked in Q3 2026 at 2.50M shares.

Which other funds hold IOVA?

Other major institutional holders of IOVA include MHR FUND MANAGEMENT LLC, Orion Investment Co, XCELSIOR ADVISOR PARTNERS LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.